Ignite Creation Date:
2024-05-06 @ 9:54 AM
Last Modification Date:
2024-10-26 @ 12:21 PM
Study NCT ID:
NCT03107273
Status:
COMPLETED
Last Update Posted:
2019-01-23
First Post:
2017-03-31
Brief Title:
Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes
Sponsor:
Centre Hospitalier Universitaire Amiens
Organization:
Centre Hospitalier Universitaire Amiens
Study Overview
Official Title:
Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEMASTEM
Brief Summary:
Myelodysplastic syndromes MDS are myeloid hemopathies characterized by ineffective clonal haematopoiesis peripheral cytopenias and a predisposition to the occurrence of acute myeloid leukemias Their diagnosis involves a cytological evaluation of the medulla while their prognosis in addition to extrinsic factors depending on the patient himself age comorbidities intrinsic factors The cytological evaluation is subject to a certain subjectivity since qualitative and the diagnosis is sometimes difficult in the absence of marker of clonality More and more studies emphasize the interest of flow cytometry CMF in the diagnosis of SMD by looking for qualitative and or quantitative aberrations of the expression of membrane markers CMF allows to establish scores Diagnosis that we have put in place within the laboratory However these studies are based on a static model that studies the phenotypic characteristics of patients at a given time but does not really reflect ineffective hematopoiesis A dynamic model for in vitro reproduction of hematopoiesis would be an innovative tool for the study of SMD This project aims to develop and standardize a system of differentiation in liquid medium of hematopoietic stem cells CSH in mature cells by studying each stage of the differentiation in terms of proliferation apoptosis and phenotypic expression HSCs will be obtained by CD34 sorting from the medullary sample at diagnosis the investigator will study cell proliferation apoptosis and the acquisition of surface markers in order to identify the quantitative and qualitative abnormalities associated with the differentiation of haematopoietic progenitors Smart This should make it possible to identify diagnostic and prognostic factors in terms of response to treatment acutism and survival
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None